scholarly journals Role of topical nadifloxacin as an empirical treatment in patients with skin and soft-tissue infections in India: A review and consensus

2021 ◽  
Vol 1 ◽  
pp. 61
Author(s):  
Rashmi Sarkar ◽  
Sushil Tahiliani ◽  
Amit Madan ◽  
Anil Abraham ◽  
Anil Ganjoo ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Antimicrobial Agents ◽  
Efflux Pump ◽  
Empirical Treatment ◽  
Cochrane Library ◽  
Extensive Literature ◽  
Soft Tissue Infections ◽  
Topical Formulation ◽  
Topoisomerase Iv ◽  
Development Of Resistance

Dermatologists often come across cases of skin and soft-tissue infections (SSTIs) which have diverse clinical presentations. Various local, systemic, and environmental risk factors predispose an individual to develop SSTIs. Topical antimicrobial agents are frequently used in superficial uncomplicated SSTIs, whereas systemic therapy is generally reserved for use in severe cases. However, emergence of resistance to these agents is becoming a common problem in clinical practice. This necessitates the use of other classes of antimicrobials for the effective treatment of SSTIs. Nadifloxacin, a potential drug belonging to the fluoroquinolone group, has various advantages such as binding to bacterial DNA gyrase and topoisomerase IV enzymes, inhibition of nor-A efflux pump, survival in acidic pH, anti-MRSA activity, and biofilms penetration. It has also shown least development of resistance since its introduction. Although its topical formulation has shown superior efficacy as an anti-acne agent, there are no specific guidelines for its appropriate use in SSTIs. Hence, a panel of experts was formed, under whose guidance an extensive literature search was performed in MEDLINE, Cochrane Library, and Science Direct databases. Using the modified Delphi technique, the available evidence was reviewed and corresponding recommendations were given for the use of topical Nadifloxacin as an empirical treatment in SSTIs.

scholarly journals Controlled and Local Delivery of Antibiotics by 3D Core/Shell Printed Hydrogel Scaffolds to Treat Soft Tissue Infections

Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2151
Author(s):  
Ashwini Rahul Akkineni ◽  
Janina Spangenberg ◽  
Michael Geissler ◽  
Saskia Reichelt ◽  
Hubert Buechner ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Antimicrobial Agents ◽  
Release Kinetics ◽  
Core Shell ◽  
Burst Release ◽  
High Morbidity ◽  
Local Concentration ◽  
Soft Tissue Infections ◽  
Antibiotic Delivery

Soft tissue infections in open fractures or burns are major cause for high morbidity in trauma patients. Sustained, long-term and localized delivery of antimicrobial agents is needed for early eradication of these infections. Traditional (topical or systemic) antibiotic delivery methods are associated with a variety of problems, including their long-term unavailability and possible low local concentration. Novel approaches for antibiotic delivery via wound coverage/healing scaffolds are constantly being developed. Many of these approaches are associated with burst release and thus seldom maintain long-term inhibitory concentrations. Using 3D core/shell extrusion printing, scaffolds consisting of antibiotic depot (in the core composed of low concentrated biomaterial ink 3% alginate) surrounded by a denser biomaterial ink (shell) were fabricated. Denser biomaterial ink (composed of alginate and methylcellulose or alginate, methylcellulose and Laponite) retained scaffold shape and modulated antibiotic release kinetics. Release of antibiotics was observed over seven days, indicating sustained release characteristics and maintenance of potency. Inclusion of Laponite in shell, significantly reduced burst release of antibiotics. Additionally, the effect of shell thickness on release kinetics was demonstrated. Amalgamation of such a modular delivery system with other biofabrication methods could potentially open new strategies to simultaneously treat soft tissue infections and aid wound regeneration.

Daptomycin Versus Other Antimicrobial Agents for the Treatment of Skin and Soft Tissue Infections: A Meta-Analysis

2010 ◽  
Vol 44 (1) ◽  
pp. 97-106 ◽  
Author(s):  
loannis A Bliziotis ◽  
Eleni Plessa ◽  
George Peppas ◽  
Matthew E Falagas
Keyword(s):  
Soft Tissue ◽  
Antimicrobial Agents ◽  
Meta Analysis ◽  
Soft Tissue Infections

From the Cochrane Library: Interventions for necrotizing soft tissue infections in adults (Preprint)

2021 ◽  
Author(s):  
Hadir Shakshouk ◽  
Camille Hua ◽  
Brandon L. Adler ◽  
Alex G. Ortega‐Loayza
Keyword(s):  
Soft Tissue ◽  
Cochrane Review ◽  
Cochrane Library ◽  
Soft Tissue Infections ◽  
Necrotizing Soft Tissue Infections ◽  
The Cochrane Library

UNSTRUCTURED Summary for the Cochrane review Interventions for necrotizing soft tissue infections in adults

Factors Associated with Mortality Following Burns Complicated by Necrotizing Skin and Soft Tissue Infections: A Systematic Review and Meta-analysis of Individual Participant Data

2021 ◽  
Author(s):  
Kevin M Klifto ◽  
Caresse F Gurno ◽  
Stella M Seal ◽  
C Scott Hultman
Keyword(s):  
Soft Tissue ◽  
Graft Survival ◽  
Burn Injury ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Individual Participant Data ◽  
Soft Tissue Infections ◽  
Factors Associated ◽  
Burn Center ◽  
Individual Participant

Abstract We reviewed studies with individual participant data of patients who sustained burn injury and subsequently developed necrotizing skin and soft tissue infections (NSTI). Characteristics and managements were compared between patients who lived and patients who died to determine factors associated with mortality. Six databases (PubMed, EMBASE, Cochrane Library, Web of Science, Scopus and CINAHL) were searched. PRISMA-IPD guidelines were followed throughout the review. Eligible patients sustained a burn injury, treated in any setting, and diagnosed with a NSTI following burn injury. Comparisons were made between burned patients who lived “non-mortality” and burned patients who died “mortality” following NSTI using non-parametric univariate analyses. Fifty-eight studies with 78 patients were published from 1970 through 2019. Non-mortality resulted in 58 patients and mortality resulted in 20 patients. Patients with mortality had significantly greater median %TBSA burned (45%[IQR:44-64%] versus 35%[IQR:11-59%],p=0.033), more intubations (79% versus 43%,p=0.013), less debridements (83% versus 98%,p=0.039), less skin excisions (83% versus 98%,p=0.039), more complications (100% versus 50%,p<0.001), management at a burn center (100% versus 71%,p=0.008), underwent less flap surgeries (5% versus 35%,p=0.014), less graft survival (25% versus 86%,p<0.001), and less healed wounds (5% versus 95%,p<0.001), compared to patients with non-mortality, respectively. Non-mortality patients had more debridements, skin excised, systemic antimicrobials, skin graft survival, flaps, improvement following surgery and healed wounds compared to mortality patients. Mortality patients had greater %TBSA burned, intubations, management at a burn center and complications compared to non-mortality patients.

Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections

2020 ◽  
Vol 19 (3) ◽  
pp. 236-241 ◽  
Author(s):  
Vasilios Petrakis ◽  
Periklis Panagopoulos ◽  
Nikolaos Papanas
Keyword(s):  
Staphylococcus Aureus ◽  
Soft Tissue ◽  
Antimicrobial Agents ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Antimicrobial Treatment ◽  
Soft Tissue Infections ◽  
Gram Positive ◽  
Positive Skin ◽  
Methicillin Resistant ◽  
Complicated Skin

New antimicrobial agents have been developed to treat infections caused by methicillin-resistant Staphylococcus aureus and other multidrug-resistant pathogens. Dalbavancin is a novel semisynthetic lipoglycopeptide antibiotic, particularly active against methicillin-resistant Staphylococcus aureus. Due to its unique pharmacological characteristics and longer half-life, it can be administered once-weekly or every 15 days and in outpatient setting. Currently, it is indicated for complicated skin and soft tissue infections, but accumulating evidence points to its off-label efficacy in osteomyelitis and endocarditis. Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment.

Sign in / Sign up

Export Citation Format

Share Document